Compare BCTX & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | REFR |
|---|---|---|
| Founded | 2014 | 1965 |
| Country | Canada | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 21.6M |
| IPO Year | 2025 | 1995 |
| Metric | BCTX | REFR |
|---|---|---|
| Price | $3.72 | $0.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 162.5K | 55.9K |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,488,642.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $380.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.48 |
| 52 Week High | $14.68 | $2.70 |
| Indicator | BCTX | REFR |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 46.13 |
| Support Level | $3.66 | $0.48 |
| Resistance Level | $4.51 | $0.83 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 74.77 | 64.81 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.